0.4905EUR+0.10%Mkt Cap: 104.71M EURP/E: —Last update: 2026-05-13
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-2.74
PEG—
P/B-3.04
P/S80.06
EV/EBITDA-3.43
EV/Revenue52.53
EPS (TTM)-0.22
EPS (Forward)-0.18
Cash Flow & Leverage
FCF Yield-10.83%
FCF Margin-866.94%
Operating CF-17.92M EUR
CapEx (TTM)222.00K EUR
Net Debt/EBITDA-0.62
Net Debt12.36M EUR
Technical
SMA 500.5086 (-3.6%)
SMA 2001.629 (-69.9%)
Beta1.11
S&P 52W Chg24.23%
Avg Vol (30d)996.28K
Avg Vol (10d)679.46K
Technical Indicators
RSI (14)46.2
MACD-0.0176
MACD Signal-0.0265
MACD Hist.+0.0089
BB Upper0.5098 EUR
BB Middle0.4784 EUR
BB Lower0.4470 EUR
BB Width13.12%
ATR (14)0.0277 EUR
Vol Ratio (20d)0.46x
52W Range
0.43652% of range3.345
52W High3.345 EUR
52W Low0.4365 EUR
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-638.99%
ROE147.28%
ROA-158.73%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-1.33
Current Ratio0.84
Quick Ratio0.68
Book Value/Sh-0.1620 EUR
Cash/Share0.1080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.199.51M
Float88.14M
Insiders13.32%
Institutions11.18%
Analyst Consensus
Rating—
Target (Mean)1.413 EUR
Target Range0.7500 EUR – 2.500 EUR
# Analysts4
Company
Market Cap104.71M EUR
Enterprise Value68.72M EUR
Revenue (TTM)1.31M EUR
Gross Profit1.31M EUR
Net Income (TTM)-27.26M EUR
Revenue/Share0.0120 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees33
Last Price0.4905 EUR
CountryFI
SectorHealthcare
IndustryBiotechnology
ISIN—